A study found that typical cholesterol exams could be missing an important indicator of heart disease risk in certain people.

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...

Using hormone replacement therapy (HRT) to reduce cardiovascular risk during menopause remains a topic of debate. The ...

She corrects the widespread misconception, claiming that eradicating fat to reduce cholesterol is "nonsense." Contrary to ...

A phase 2 trial shows that olpasiran, an RNA-based therapy, reduces lipoprotein(a) [Lp(a)] levels by more than 95% in ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

Cholesterol is a fatty substances which collects in our blood vessels, and is caused by things like diet, exercise, and ...

According to a professor from ZOE - you know you do not have to eliminate fat completely and can lower your bad cholesterol ...